Skip to main content
. 2016 Apr 25;34(20):2380–2388. doi: 10.1200/JCO.2015.62.4544

Fig A4.

Fig A4.

Event-free survival (EFS) comparison by methotrexate regimen, randomly assigned participants age 10 years and older assigned to prednisone (enrolled after April 2008). The 4-year EFS rates Capizzi escalating-dose methotrexate (C-MTX) and high-dose methotrexate (HD-MTX) were 77.0 ± 4.8% and 79.1 ± 4.3%, respectively. Note that there was insufficient follow-up to report 5-year EFS.